Indoco Remedies gets USFDA’s approval for Lacosamide Injection

08 Apr 2022 Evaluate

Indoco Remedies has received an approval from the United States Food & Drug Administration (USFDA) for ANDA Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL) single-dose vials. The generic Lacosamide Injection USP of the company is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Vimpat Injection of UCB, Inc.

Lacosamide injection is indicated for the prevention and control of seizures. It is an anticonvulsant/ antiepileptic drug. According to available IQVIA, sales data for Vimpat Injection is approximately $43.8 million, growing at 25%.

Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs) in India.

Indoco Remedies Share Price

231.20 -3.60 (-1.53%)
01-Jan-2026 13:50 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1717.30
Dr. Reddys Lab 1250.00
Cipla 1500.35
Zydus Lifesciences 913.35
Lupin 2099.90
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×